| 1 |
34315388 | New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range. | 2022 |
1 |
| 2 |
34923743 | Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies. | 2022 Mar |
1 |
| 3 |
35007861 | Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients. | 2022 Feb 15 |
2 |
| 4 |
35403641 | Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer. | 2022 May 17 |
2 |
| 5 |
32236267 | Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer. | 2021 Jan 21 |
1 |
| 6 |
32173687 | Novel conjugates of endoperoxide and 4-anilinoquinazoline induce myeloma cell apoptosis by inhibiting the IGF1-R/AKT/mTOR signaling pathway. | 2020 May 21 |
3 |
| 7 |
32411653 | Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity. | 2020 |
1 |
| 8 |
31387063 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. | 2019 Nov 1 |
1 |
| 9 |
31424613 | Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma. | 2019 Oct 4 |
1 |
| 10 |
29194843 | Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment. | 2018 Mar 2 |
1 |
| 11 |
29486966 | Radiosynthesis and biological evaluation of 18F-labeled 4-anilinoquinazoline derivative (18F-FEA-Erlotinib) as a potential EGFR PET agent. | 2018 Apr 1 |
1 |
| 12 |
30065769 | Structure based design and anti-breast cancer evaluation of some novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor inhibitors. | 2018 Aug |
3 |
| 13 |
30508379 | Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold. | 2018 Dec 27 |
3 |
| 14 |
31038021 | Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor. | 2018 Oct - Dec |
3 |
| 15 |
27688180 | Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. | 2017 Jan 5 |
2 |
| 16 |
28279846 | Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors. | 2017 Apr 21 |
1 |
| 17 |
28711702 | Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. | 2017 Sep 29 |
1 |
| 18 |
26829280 | Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. | 2016 Mar 3 |
1 |
| 19 |
26848869 | Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts. | 2016 Jun 14 |
2 |
| 20 |
27039919 | 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity. | 2016 |
3 |
| 21 |
27093574 | Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines. | 2016 May 2 |
3 |
| 22 |
27118497 | Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors. | 2016 Jun 1 |
1 |
| 23 |
27288180 | Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. | 2016 Aug 15 |
1 |
| 24 |
26106875 | Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands. | 2015 Aug 7 |
3 |
| 25 |
26446567 | Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells. | 2015 Dec |
2 |
| 26 |
26633023 | Discovery of Potent Antiproliferative Agents Targeting EGFR Tyrosine Kinase Based on the Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine Scaffold. | 2015 |
2 |
| 27 |
27169285 | Synthesis of new 4-anilinoquinazoline analogues and evaluation of their EGFR inhibitor activity. | 2015 Dec |
1 |
| 28 |
23402383 | Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents. | 2014 Apr |
3 |
| 29 |
25468044 | Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. | 2014 Dec 15 |
3 |
| 30 |
22867529 | Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. | 2013 Mar |
2 |
| 31 |
23315145 | Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. | 2013 Apr |
1 |
| 32 |
23640754 | Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. | 2013 Jun |
2 |
| 33 |
23847159 | 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines. | 2013 Sep |
1 |
| 34 |
23936329 | Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors. | 2013 |
2 |
| 35 |
23962660 | Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity. | 2013 Oct 1 |
2 |
| 36 |
23973168 | Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. | 2013 Oct 1 |
2 |
| 37 |
23988354 | Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. | 2013 Oct 1 |
1 |
| 38 |
24183742 | Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. | 2013 Dec 15 |
5 |
| 39 |
22043991 | Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds. | 2012 May |
1 |
| 40 |
22204331 | Exploration of chemical space based on 4-anilinoquinazoline. | 2012 |
1 |
| 41 |
22309911 | Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents. | 2012 Mar |
1 |
| 42 |
22723174 | Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition. | 2012 Aug |
2 |
| 43 |
22959248 | Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. | 2012 Oct 1 |
2 |
| 44 |
21130075 | Determining the binding mode and binding affinity constant of tyrosine kinase inhibitor PD153035 to DNA using optical tweezers. | 2011 Jan 7 |
1 |
| 45 |
21478021 | Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes. | 2011 May 1 |
1 |
| 46 |
21553932 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. | 2011 Jun |
1 |
| 47 |
21570843 | Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. | 2011 Jun 15 |
2 |
| 48 |
21789172 | AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. | 2011 |
3 |
| 49 |
19455431 | In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs. | 2010 Mar |
1 |
| 50 |
19720054 | Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. | 2010 Jan 15 |
1 |